Engineering biology

The UK government defines engineering biology as the design, scaling and commercialisation of biology-derived products and services that can transform sectors or produce existing products more sustainably. It draws on the tools of synthetic biology to create the next wave of innovation in the bioeconomy. In the UK context, the emphasis is not just on scientific innovation, but on translating breakthroughs into scalable, real-world solutions across industries.

With the potential to generate $2 to 4 trillion of annual economic impact globally between 2030 and 2040, engineering biology is ripe with opportunity. As one of the frontier technologies in the Digital and Technologies Sector Plan, the engineering biology sector is a key focus in the UK’s Modern Industrial Strategy. Take advantage of this momentum and join Europe’s leading ecosystem for start-up creation and private investment, benefiting from a world-class research base and strong government support.

Opportunity highlights

Invest in engineering biology and pioneer technologies across a range of applications.

Health and life sciences

Engineering biology is crucial for health innovation, with tremendous potential for improved patient outcomes through more precise and personalised therapies and treatments. The UK’s personalised medicine market is expected to be worth £45 billion by 2035, up from £20 billion in 2024, giving investors an attractive and rapidly growing market for engineering biology solutions in the life sciences sectors.

Chemicals and materials

With £61 billion worth of exports in 2024, the UK’s chemical sector offers a wide-ranging and high demand industry for engineering biology applications. Solutions can enable sustainable production of existing chemicals and entirely new materials, and opportunities span bio-based polymers, sustainable textiles and advanced materials for electronics and aerospace.

Agriculture and food

The UK agri-food sector is a crucial part of the country’s economy, accounting for £153.2 billion, or 6.2%, of the UK’s GVA (Gross Value Added) in 2023. Engineering biology applications offering investment opportunities include developing crops with greater resistance to pests, disease and climate challenges, alongside manufacturing alternative proteins and biological pesticides.

Low carbon fuels

Harness engineering biology and invest in sustainable aviation fuels, marine biofuels and advanced biofuels that can decarbonise transport sectors while supporting the UK's net-zero commitments. Demand for biofuels in the UK is projected to rise to 39,000 barrels of oil equivalent a day, presenting an expanding market for investors in the sector.

Commercial opportunity

The UK engineering biology sector has strong commercial readiness across multiple verticals. As the European leader in synthetic biology, the UK enjoys a large and rapidly expanding market projected to reach $3 billion by 2030 with a 17.9% CAGR (compound annual growth rate). Finance for the sector is also on the rise, with the UK biotech sector attracting £1.23 billion in venture capital investment in the first half of 2025 alone. Recent successful exits, including major acquisitions and IPOs (initial public offerings), highlight the UK’s attractive commercial pathway. Government allocation processes through UK Research and Innovation (UKRI) provide regular funding cycles, while proven technologies across the health, materials and agriculture sectors demonstrate immediate deployment advantages for investors.

Key UK assets

The UK's engineering biology ecosystem spans multiple regions, with world-class research institutions and growing industrial clusters.

London, Oxford and Cambridge

The area, known as the Golden Triangle, houses the UK's largest concentration of biotech R&D (research and development). It boasts strong start-up clusters, world-leading research at Cambridge's MRC Laboratory of Molecular Biology and Oxford's biopharmaceuticals expertise. Combined with London's thriving engineering biology ecosystem and financial markets, there is unparalleled access to both innovation and capital.

Bristol and South West England

The region has strong capabilities in cell therapies, vaccines and novel foods through BrisSynBio at the University of Bristol and the ScienceCreates incubator. It combines academic excellence with growing commercial clusters in sustainable biotechnology applications.

Yorkshire and Teesside

BioYorkshire is actively supporting research and collaboration in biotechnology applications while the Centre for Process Innovation's National Biologics Manufacturing Centre in Teesside is working to increase the UK’s biologics manufacturing capabilities.  With specialisms in novel foods, bioprocessing and industrial applications, the region provides access to world-class expertise for investors.

North West England

The region is home to the Future Biomanufacturing Research Hub and strengths in microbiology, vaccines and gas fermentation. The North West offers key assets for research and investment like the Unilever's Materials Innovation Factory and major biofoundry capabilities. Additionally, the Liverpool City Region Investment Zone has a strong focus on life sciences innovation, creating an attractive ecosystem for investments in engineering biology health applications.

Scotland

Scotland boasts leading research capabilities in animal biology, industrial biotech and mammalian cells. Facilities like the Roslin Institute, Centre for Mammalian Synthetic Biology and Industrial Biotechnology Innovation Centre (IBioIC) are supporting cutting-edge advances in the sector. The Forth Green Freeport and Glasgow City Region Investment Zone provide enhanced investment incentives for engineering biology companies, making for a profitable landing pad into the UK.

R&D capability

The UK's engineering biology research infrastructure is a world-leading innovation ecosystem. UKRI, the country’s leading research funding agency, has invested over £800 million in engineering biology research since 2007, establishing the UK as a global leader in the field. UKRI has multiple programmes targeting the sector, one of its strategic priority areas. The government's £196 million National Engineering Biology Programme will continue this effort, supporting researcher-led projects targeting transformative applications.

Key facilities for engineering biology R&D include the London BioFoundry at Imperial College, and multiple Catapult centres including CPI and Cell and Gene Therapy Catapult. There is an extensive network of biofoundries providing automated, high-throughput capabilities. By investing in the UK, firms can access funding opportunities, enter innovation partnerships and benefit from cutting-edge research.

Business and government support

The UK is delivering sustained support for engineering biology through the Digital and Technologies Sector Plan. Beyond the £196 million for a National Engineering Biology Programme, a further investment of £184 million has been announced for an Engineering Biology Scale-up Infrastructure Programme, supporting the development of an attractive ecosystem for investment.

A second round of the Engineering Biology Sandbox Fund has also been launched, helping to move forward innovation-friendly regulations for the sector. Furthermore, thanks to the Genetic Technologies (Precision Breeding) Act 2023, companies can access faster routes to market for precision-bred products, giving the UK a competitive regulatory advantage.

Talent

The UK provides access to a 9.4 million-strong STEM (science, technology, engineering and mathematics)workforce and is ranked second in Europe for qualified workforce, only behind Ireland in 2023. In the 2021/22 academic year, 42% of all UK graduates had completed STEM disciplines, creating a robust pipeline of engineering biology talent for investors.

Specialized training through Institutes of Technology, the UKRI Accelerator Programme for Engineering Biology, and doctoral training programmes ensure sector-specific skills development. Early career support includes entrepreneurial training, via networks in industrial biotechnology and SynbiCITE, the UK's national industrial translation centre for engineering biology. The Innovation-to-Commercialisation (ICURe) programme develops commercialisation expertise and two new doctoral focal award centres will further expand the engineering biology talent pipeline.